Our results highlighted that baseline polypharmacy was independently associated with age, number of additional diseases, baseline DAS-28 CRP scores, and bDMARD use in the RA patients and aged 65 or above and CCI scores in PsA the patients. This evidence concerns the gene CRP and rheumatoid arthritis.